RxDoctor Payments DataLook up a doctor →

Kelly McCants, MD

Advanced Heart Failure and Transplant Cardiology · Winter Park, FLNPI 1689723280

Payments from drug & device makers

$474,624in general payments, 2019–2025

Across 774 payments — averaging $613.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$171K
  • Janssen Scientific Affairs, LLC$56K
  • Boehringer Ingelheim$50K
  • Novartis$47K
  • AstraZeneca$37K
  • Abbott$33K
  • plus $79K from 25 others

What the payments were for

  • Consulting fees$78,81018%
  • Speaking & faculty fees$273,58561%
  • Travel & lodging$71,68116%
  • Food & beverage$21,0105%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$474,624 in reported general payments places this provider in the 95th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

See all advanced heart failure and transplant cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$67,636
Medicare patients
234
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan73$77,553
FarxigaDapagliflozin Propanediol35$32,269
EliquisApixaban27$29,516
JardianceEmpagliflozin19$23,757
Tacrolimus59$6,725
Sirolimus15$6,233
Mycophenolate Mofetil39$4,078
Potassium Chloride73$2,981
Bumetanide69$2,253
Metoprolol Succinate100$1,401
Carvedilol171$1,001
Torsemide31$776
Losartan Potassium110$754
Digoxin27$662
Furosemide136$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$47,217$77,55373 claims
AstraZenecaFarxiga$37,375$32,26935 claims
PfizerEliquis$20,402$29,51627 claims
Boehringer IngelheimJardiance$50,304$23,75719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

Other advanced heart failure and transplant cardiology in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →